靶向治疗
小分子
医学
食品药品监督管理局
药品
癌症治疗
计算生物学
靶向给药
药物发现
药理学
生物信息学
癌症
生物
内科学
遗传学
作者
Guoqiang Sun,Rong Ding,Z. Li,Fan Wu,Xiao Li,Hongxin Cao,Yufeng Cheng,Weiwei Tang,Yangbai Sun
标识
DOI:10.3389/fcell.2021.694363
摘要
Research on molecular targeted therapy of tumors is booming, and novel targeted therapy drugs are constantly emerging. Small molecule targeted compounds, novel targeted therapy drugs, can be administered orally as tablets among other methods, and do not draw upon genes, causing no immune response. It is easily structurally modified to make it more applicable to clinical needs, and convenient to promote due to low cost. It refers to a hotspot in the research of tumor molecular targeted therapy. In the present study, we review the current Food and Drug Administration (FDA)-approved use of small molecule targeted compounds in tumors, summarize the clinical drug resistance problems and mechanisms facing the use of small molecule targeted compounds, and predict the future directions of the evolving field.
科研通智能强力驱动
Strongly Powered by AbleSci AI